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1It is well accepted that the presence of nonobstructive ath-erosclerotic plaques, particularly those with high-risk mor-
phological (HRM) features, is associated with an increased 
risk of future cardiovascular disease events.1,2 This observa-
tion has led to proposals to use data on nonobstructive plaque 
characteristics (if available) to alter the thresholds for prescrib-
ing lipid-lowering drugs for primary prevention.3,4 A related 
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and yet unresolved question is whether the antiatherosclerotic 
benefits of statins may be differentially imparted depending 
on the severity of the underlying atherosclerotic process. This 
question is of substantial importance because an association 
between atherosclerotic disease morphology and statin effi-
cacy would provide a second reason to consider structural 
disease characteristics when deciding on primary prevention 
therapy.
Atherosclerosis is a systemic inflammatory condition5; 
the anti-inflammatory actions of statins is one of its most 
important beneficial effects on atherosclerosis.6 Arterial imag-
ing using 18-fluorodeoxy glucose positron emission tomog-
raphy and computed tomography (FDG-PET/CT) is used 
to reproducibly measure atherosclerotic inflammation.7–10 
Atherosclerotic FDG uptake can be quantified noninvasively 
and significantly correlates with systemic inflammatory bio-
markers,11 macrophage infiltration, and inflammatory cell 
gene expression within the arterial wall.12,13 Furthermore, 
it provides an independent marker of risk for future athero-
thrombotic events14,15 and is modifiable by statin therapy.9,16 
The majority of FDG-PET imaging studies have focused on 
extracoronary vessels.7,10,17 However, successful evaluation of 
coronary FDG uptake has been reported previously18 and has 
recently focused on the left main coronary artery (LMCA) 
segment, which does not have an epicardial course and thus 
lends itself to measurement of FDG uptake.19
We hypothesized that atherosclerotic inflammation is great-
est within LMCA manifesting HRM features. Accordingly, in 
this prospective treatment study, we tested the hypothesis that 
the anti-inflammatory actions of atorvastatin are greatest in 
LMCA with (versus without) HRM.
Methods
Study Design
This study is part of a larger randomized double-blind trial that was 
conducted at 10 US centers to investigate the impact of atorvastatin 
therapy on arterial wall inflammation. The study complies with the 
Declaration of Helsinki. The protocol was reviewed and approved by 
each center’s institutional review board, and all participants provid-
ed written informed consent before any study procedures. Analysis 
of FDG uptake in the LMCA, carotid arteries, and aorta was per-
formed before unblinding of the data. In the current study, we used 
computed tomographic angiography (CTA) images and performed a 
blinded analysis of plaque composition in carotids and coronary ar-
teries and additionally assessed the relationship between FDG uptake 
and high-risk plaque morphology. Permission was received from the 
Partners Healthcare Institutional Review Board to perform these ad-
ditional analyses on the anonymized images. The primary end point 
of the study, evaluating the effect of statin therapy on large-vessel 
inflammatory activity (assessed by FDG PET/CT), was previously 
reported.9
Patients
One hundred and sixty-three subjects were initially screened, and 83 
subjects (78% men; median age: 59 years; range: 37–78 years) un-
derwent baseline FDG-PET/CT imaging. Criteria for inclusion were 
individuals aged 30 to 80 years with documentation or history of any 
one of the following: (1) coronary artery disease, (2) carotid artery 
disease, (3) cerebrovascular disease, (4) peripheral arterial disease 
(ankle–brachial index ≥0.5 and ≤0.9), (5) type 2 diabetes mellitus, 
and (6) body mass index 30 to 40 kg/m2 or waist circumference >102 
cm in men and >88 cm in women. Subjects were excluded if they had 
a history of (1) type 1 diabetes mellitus, (2) significant cardiovascular 
event or intervention within 12 weeks of screening, (3) significant 
heart failure (ie, New York Heart Association class III or IV), (4) 
hepatobiliary disease, (5) chronic systemic inflammatory condition 
(such as rheumatoid arthritis or psoriasis), or (6) chronic infection. In 
addition, eligible subjects were required to have low-density lipopro-
tein cholesterol level ≥60 mg/dL and triglyceride level <350 mg/dL 
and were required to be statin naive or taking no more than low-dose 
statins (defined as atorvastatin ≤10 mg, simvastatin ≤20 mg, rosuvas-
tatin ≤5 mg, pravastatin ≤40 mg, or fluvastatin ≤40 mg).
After the initial clinical screening, subjects underwent baseline 
imaging with FDG-PET/CT. Because the study was originally de-
signed to evaluate the effect of statin treatment on arterial wall in-
flammation, subjects without evidence of arterial inflammation (ie, 
only subjects with target-to-background ratios [TBR] ≥1.6 in either 
the aorta or carotids were included) at baseline were excluded be-
fore randomization, resulting in the exclusion of ≈10% of the initially 
screened population. Follow-up FDG-PET/CT images were obtained 
after 12 weeks of atorvastatin therapy.
FDG-PET/CT Imaging
FDG-PET/CT imaging was performed using previously reported 
approaches.9 Briefly,18F-FDG was administered intravenously (≈10 
mCi for a 70 kg patient) after an overnight fast, and imaging was 
performed 90 minutes after FDG injection using a hybrid PET/
CT scanner (Seimens Biograph 64 or similar). To suppress myo-
cardial FDG uptake, subjects were instructed to consume a low-
carbohydrate, high-fat diet starting with the dinner meal (or 5.00 pm, 
whichever comes first), the evening before the day of FDG-PET/
CT imaging, to suppress myocardial FDG uptake. An attenuation 
correction CT scan using 140 kVp was performed followed by PET 
imaging of the neck and chest, with 15-minute acquisitions per bed 
position. The reconstruction of attenuation-corrected images was 
performed using ordered subset expectation maximization algo-
rithm. All patients had a blood sugar concentration <200 mg/dL at 
the time of imaging.
Table. Baseline Characteristics of Study Subjects
 
All Subjects 
(n=55)
Individuals With 
HRM in the LMCA  
(n=15)
Individuals 
Without HRM 
in the LMCA  
(n=40) P Value
Age, y 61±9 58±8 62±9 0.17
Male sex 41 (76) 12 (80) 29 (74) 1.00
BMI, kg/m2 31.5±7.8 31.3±4.5 32.9±11.4 0.57
Current 
smoker
17 (31) 6 (37) 11 (28) 0.53
Race (white) 45 (83) 12 (80) 33 (85) 0.69
Type 2 
diabetes 
mellitus
19 (34) 7 (44) 12 (31) 0.37
Prestudy 
low-dose 
statin use
35 (64) 9 (56) 26 (67) 0.54
LDL 
cholesterol, 
mg/dL
101.8±24.8 97.7±25.4 103.4±24.7 0.95
HDL 
cholesterol, 
mg/dL
46.3±14.9 46.07±12.5 46.36±15.9 0.46
Values are presented as mean±SD or n (%). BMI indicates body mass index; 
HDL, high-density lipoprotein; HRM, high-risk morphology; LDL, low-density 
lipoprotein; and LMCA, left main coronary artery.
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Measurement of Coronary Artery FDG Uptake
PET/CT images were analyzed using previously detailed methods.18,19 
Investigators were blinded to the clinical history and temporal se-
quence of the images. Subsequently, the data sets (week 0 and 12 im-
ages) were batch analyzed after coregistration of PET and CT images 
(Leonardo TrueD; Siemens, Forchheim, Germany). Maximum stan-
dardized uptake value of FDG was measured in LMCA by placing 
4 regions of interest at the LMCA ostium, 5 and 10 mm distal to the 
ostium, and LMCA bifurcation. The measurements from those LMCA 
locations were averaged to produce mean of maximum LMCA stan-
dardized uptake value. Care was taken to avoid the spillover activ-
ity from the myocardium, as performed in a previous study by our 
group.18 The fact that coronary artery activity measurements were 
limited to the LMCA, a nonepicardial segment of the coronary tree, 
facilitated the avoidance of myocardial activity. Target-to-background 
ratios were derived from the ratio of the arterial standardized uptake 
value to background venous blood standardized uptake value from the 
superior vena cava. In addition, FDG uptake was measured in the aorta 
and carotids using previously described methods.9
Measurement of Arterial Inflammation in the Aorta 
and Carotids
FDG uptake (TBR) was evaluated in 3 extracoronary arterial loca-
tions (right and left carotid and aorta). The extracoronary artery with 
the highest FDG uptake at baseline was identified as the index ves-
sel, as previously described.9 The mean TBR of the index vessel was 
defined as the average of the maximum TBR activity for all of the 
axial segments that compose the index vessel.
CT Angiography
Coronary CTA, to assess coronary artery plaque morphology, was 
performed in helical mode on multidetector CT scanners with ≥64 
slices. Imaging parameters included rotation time of ≤420 ms, tube 
current of ≈750 to 850 mAs (effective), and voltage of 120 kVp. 
Image acquisition characteristics were slice thicknesses of 0.75 mm 
and pitch of 0.2 to 0.4. Iopamidol 300 mg/mL or a similar drug was 
used as an intravenous contrast agent and infused at 5 to 6 mL/s. 
Immediately after coronary CT angiography, the table was reposi-
tioned for acquisition of carotid images. Settings for carotid CT scan-
ning were as follows: pitch 2.8, rotation time of ≤500 ms, tube current 
of ≈180 to 300 mA, and voltage of 120 kVp.
Assessment of Atherosclerotic Plaque Morphology 
in the Coronary Arteries
Evaluation of the CTA images was performed while blinded to PET 
data and clinical information. Plaque morphology was assessed in 
the LMCA. HRM plaques in the LMCA were identified by presence 
of noncalcified or partially calcified plaques as described in previous 
studies.20,21 An analysis examining morphological features of athero-
sclerotic plaques in the entire coronary arterial tree and carotid circu-
lation was also performed (please refer to the Table I and Figure I in 
the Data Supplement, respectively).
Figure 1. Study flow. Out of 163 subjects who were initially screened, 83 subjects underwent baseline 18F-flurodeoxyglucose positron 
emission tomographic (FDG-PET)/computed tomographic (CT) scan followed by statin treatment with atorvastatin. Follow-up FDG-PET 
scan was performed after 12-wk statin therapy. Seventy-one subjects completed the study, and 68 had evaluable PET/CT images. There-
after, an independent reader analyzed 55 evaluable coronary and carotid computed tomographic angiography (CTA) images while blinded 
to PET data.
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Assessment of Blood Biomarkers
C-reactive protein (CRP) and matrix metalloproteinase-3 (MMP-3) 
concentrations were obtained at baseline and 12 weeks. Serum bio-
marker analyses were performed in batches.
Statistical Analysis
Descriptive data are presented as mean±SD for continuous normally 
distributed variables, median (interquartile range) for continuous 
non-normally distributed data, and frequency with proportions for 
nominal variables, as appropriate. Independent samples t test was 
used for cross-sectional comparison of normally distributed continu-
ous variables. Mann–Whitney U test was used for the similar analyses 
of continuous variables without normal distribution (such as CRP). A 
linear regression model was fitted to adjust for potential confounding 
factors on the effects of statin therapy in reduction of FDG uptake 
(TBR). The potential confounders for adjustment were selected based 
on the previous studies or clinical relevance. In the linear regression 
model to adjust for baseline left main TBR, we used tertiles of base-
line TBR. Adjustment for Fisher exact test was performed for com-
parison of dichotomous variables. Pearson correlation coefficient (R) 
was used to assess correlations between continuous variables once 
normal distribution was verified, and Spearman ρ was reported as 
correlation coefficient for non-normally distributed variables. Two-
tailed probability values are reported, and statistical significance 
is defined as P<0.05. All statistical analyses were performed using 
SPSS version 22 (IBM, Armonk, NY).
Results
Baseline characteristics of study subjects are detailed in the 
Table. Seventy-one subjects completed the 12-week treat-
ment period. In 68 of those subjects, PET/CT image qual-
ity was sufficient to analyze FDG uptake in the LMCA and 
extracoronary vessels (ie, aorta and carotids). Fifty-five sub-
jects provided adequate-quality coronary CTA images to 
assess plaque morphology in the LMCA and carotid arteries 
(Figure 1).
Left Main Coronary Arteries Containing High-
Risk Plaque Morphological Features Have Greater 
Arterial Wall Inflammation
LMCA inflammation (TBR) was higher in LMCA with 
HRM (defined as noncalcified or partially calcified plaque) 
than those without HRM ([mean±SE]: 1.95±0.43 versus 
1.67±0.32; P=0.043; Figures 2 and 3). A similar relationship 
between plaque morphology (as determined by CTA) and arte-
rial inflammation (as determined by FDG-PET/CT) was seen 
in the carotid arteries (see Figure I in the Data Supplement).
Statins Reduce Left Main Coronary Artery 
Inflammation, an Effect More Pronounced Within 
Advanced Coronary Lesions
We evaluated the impact of statin therapy on LMCA and 
observed that after 12 weeks of statin therapy, FDG uptake 
was reduced in LMCA with HRM but not in LMCA with-
out HRM (12-week baseline change in TBR [95% confi-
dence interval]: −0.18 [−0.35 to −0.004] versus 0.09 [−0.06 
to 0.26]; P=0.02; Figure 4). This relationship remained sig-
nificant in a multivariate model after adjusting for prestudy 
statin use and statin dose after randomization (β=−0.286; 
P=0.02). The relationship remained statistically signifi-
cant after adjusting for baseline TBR (β=−0.26; P=0.04). 
Additionally, the relationship between LMCA plaque 
morphology and change in LMCA inflammation (TBR) 
after atorvastatin remained significant after adjusting for 
body mass index (β=−0.27; P=0.02) and after adjusting for 
baseline low-density lipoprotein and statin dose (β=−0.27; 
P=0.038).
Association Between Imaging Measures and Serum 
Biomarkers
For the comparison between blood biomarkers and coronary 
plaques, we assessed plaque morphology across the entire 
coronary tree (see Data Supplement). Because of the rela-
tive abundance of plaques across the entire coronary tree, 
we were able to use a more stringent definition of HRM, 
in this case, plaques with both positive remodeling and low 
attenuation (double positives). At baseline, CRP was signifi-
cantly higher in subjects with HRM than those without HRM 
within the entire coronary arterial tree (median [interquar-
tile range]=3.6 [1.0–4.8] mg/L versus 1.3 [0.6–2.5] mg/L; 
P=0.01). We did not observe significant association between 
CRP concentrations and LMCA inflammation (TBR), 
although we observed a correlation between serum MMP-3 
and LMCA inflammation (TBR; ρ=0.31; P=0.04; R=0.42; 
P=0.004).
Left Main Coronary Artery Inflammation 
Correlates With Inflammation in Extracoronary 
Arteries
At baseline, LMCA inflammation (TBR) correlated with 
inflammation (TBR) in the aorta (r=0.6; P<0.001), carotid 
Figure 2. Association between high-risk plaque morphology and 
18F-flurodeoxyglucose (FDG) uptake in left main coronary artery 
(LMCA). LMCA inflammation (target-to-background ratio [TBR]) in 
the index vessel was significantly higher in subjects with high-risk 
morphology (HRM) than those without HRM (partially calcified 
plaque/noncalcified plaque [NCP/PCP]) in the underlying coro-
nary segment as detected by coronary computed tomographic 
angiography. Error bars represent SEM.
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vessel (r=0.32; P=0.04), and index vessel (r=0.49; P=0.001; 
Figure 5A). Likewise, in response to 12-week atorvastatin 
treatment, changes in LMCA inflammation (TBR) cor-
related with changes in extracoronary arterial inflamma-
tion (ΔAorta TBR versus ΔLMCA TBR: r=0.51; P=0.001; 
ΔIndex vessel TBR versus ΔLMCA TBR: r=0.33; P=0.04; 
Figure 5B).
Higher Extracoronary Arterial Inflammation Is 
Associated With Presence of High-Risk Coronary 
Structural Features
Furthermore, the TBR (inflammation) in the aorta was associ-
ated with the presence of HRM coronary plaque features (by 
CTA) such that subjects with higher aortic TBR (≥median) 
exhibited a higher frequency of high-risk structural plaque 
features throughout the coronary tree (44% versus 13%; 
P=0.02; Figure 6).
Discussion
This first study examining the impact of statins on coronary 
artery inflammation yielded several novel observations. First, 
we provide initial evidence, in the coronary circulation, that 
coronary artery FDG accumulation, a marker of atherosclerotic 
inflammation, associates with HRM. Second, we demonstrate 
that statins result in a reduction in coronary inflammation, 
primarily in atherosclerotic plaques manifesting HRM. Fur-
thermore, we demonstrate that statin-induced therapeutic 
modulation of extracoronary artery FDG uptake parallels 
changes in coronary arterial FDG uptake. Together, these find-
ings highlight the systemic nature of atherosclerotic arterial 
inflammation and also suggest that statin therapy may have its 
greatest impact on more advanced atherosclerotic disease.
The key finding of this study is the observation that the 
anti-inflammatory effect of statins is seen primarily within 
Figure 4. Statin therapy results in a greater reduction of 
18F-flurodeoxyglucose (FDG) uptake in left main coronary artery 
(LMCA) with high-risk morphology (HRM). Changes in LMCA 
target-to-background ratio after 12-wk statin therapy were more 
pronounced in arteries with HRM in coronary computed tomo-
graphic angiography. Error bars represent SEM. NCP indicates 
noncalcified plaque; and PCP, partially calcified plaque.
Figure 3. Focal 18F-flurodeoxyglucose 
(FDG) uptake in patients with high-risk 
plaque morphology in the left main 
coronary artery (LMCA). Fused positron 
emission tomographic (PET)/computed 
tomographic (CT) image showing intense 
and focal FDG uptake in the LMCA, in 
orthogonal images (A and B), corre-
sponding maximum intensity projection–
reconstructed computed tomography 
angiographic (CTA) image of LMCA with 
noncalcified plaque (arrow; C), and axial 
CTA showing a cross-sectional view (D) of 
an additional plaque in the right coronary 
artery manifesting positive remodeling 
and low attenuation (arrow) in the same 
subject.
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more advanced lesions. The association between plaque mor-
phology and statin effect was evident in both the coronary and 
extracoronary circulation and remained robust after correct-
ing for potential confounders such as baseline TBR, prestudy 
statin use, low-density lipoprotein concentration, and statin 
dose. Accordingly, the findings of this study provide addi-
tional support for the hypothesis that assessment of atheroscle-
rosis, including arterial wall inflammatory activity, might help 
to identify individuals who would derive the greatest benefit 
from statin therapy (even among individuals already deemed 
to be at increased risk using traditional risk calculators).22,23 
This assertion is conceptually in-line with findings from the 
MESA study (Multi-Ethnic Study of Atherosclerosis), in 
which among individuals eligible for primary prevention, 
the majority of CHD and CVD events occurred in those with 
coronary artery calcium scores >100.22 From that, the authors 
suggested that preventative therapies should be preferentially 
prescribed to individuals with imaging evidence of more 
advanced atherosclerotic disease.
Similarly, Emami et al24 recently demonstrated that the 
presence of nonobstructive atherosclerotic plaques is associ-
ated with an increased risk of future atherosclerotic cardio-
vascular disease events and that incorporating information on 
nonobstructive coronary artery disease results in more accu-
rate allocation of statin therapy. Our findings add an important 
additional consideration, by indicating that the underlying 
plaque morphology may additionally affect the local effi-
cacy of statins. Together, these findings suggest that available 
Figure 5. Extracoronary arterial 18F-flu-
rodeoxyglucose (FDG) uptake parallels 
left main coronary artery (LMCA) FDG 
uptake. Index vessel FDG uptake (target-
to-background ratio [TBR]) at baseline 
(A) and changes during the 12-wk treat-
ment period (B) significantly correlated 
with baseline LMCA TBR and changes in 
LMCA TBR, respectively.
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imaging data might be useful for guiding treatment decisions 
on the use of statins or newer antiatherosclerotic approaches, 
especially in cases where there may be relative equipoise when 
deciding on primary prevention. Given the likely emergence 
of several new pharmacological tools (such as novel lipid-
lowering drugs and anti-inflammatory drugs) with which to 
reduce the risk of incident atherothrombotic events, the medi-
cal community will likely experience a greater need to better 
allocate those new treatments, a paradigm that is in-line with 
the contemporary emphasis on precision medicine.25
In this study, we also tested the hypothesis that athero-
sclerotic inflammatory activity (represented as FDG uptake in 
LMCA) is highest in coronary plaques with HRM. Although 
the relationship between HRM and inflammation has been 
previously reported for the carotids,26,27 the current study is 
the first to extend that observation to the coronary circulation. 
This observation provides further validation of FDG-PET/CT 
imaging as a tool to characterize proximal coronary athero-
sclerosis, in that it demonstrates that coronary FDG uptake 
(by PET) associates with high-risk structural features that are 
identified using an orthogonal technique (CTA).
Furthermore, we investigated the relationship between 
inflammation in coronary and extracoronary vessels. In this 
evaluation, we observed several important associations. First, 
we found that individuals with higher extracoronary arterial 
inflammation had greater coronary inflammation and were 
also more likely to have coronary plaques containing high-
risk structural features. Furthermore, we observed that the 
anti-inflammatory actions of statins were similarly manifested 
in the extracoronary and coronary circulation. These observa-
tions provide additional confidence that the data derived by 
looking at the large arteries (which are much more amena-
ble to imaging) provide important insights into the coronary 
atherosclerotic milieu (where the atherothrombotic events of 
greatest concern originate). The data also provide additional 
insights as to why imaging of the aorta with FDG-PET/CT 
functions as an independent marker of risk of future CV 
events.14,15
Finally, we studied the relationship between both plaque 
morphology and inflammation and established serum proin-
flammatory biomarkers, MMP-3 and CRP. MMP-3 has been 
shown to correlate with inflammation (FDG uptake) in the 
aorta,11 and here, we replicate that finding but further demon-
strate that this relationship extends to the coronary artery as 
well. Similar to other groups, we show a significant associa-
tion between CRP and high-risk coronary plaque features.28 
Collectively, our findings emphasize the systemic nature 
of atherosclerosis and arterial inflammation by providing 
insights on the biological links between resident plaques in 
both large and small arteries and circulating proinflammatory 
markers.
Limitations
Of the patients enrolled in the larger randomized controlled 
prospective study, this study was limited to only those patients 
with evaluable CTA images and, thus, limits the generalizabil-
ity of the results, In this subset of patients, a smaller propor-
tion had CT evidence of high-risk plaques and perhaps may 
have limited our ability to detect a consistent relationship with 
CRP and MMP-3. It is also worth noting that analyses were 
not sufficiently powered to assess the impact of statin dose 
(high dose versus low dose) on LMCA.
In addition, coronary CTA was performed at a single time 
point, thereby precluding longitudinal assessment of changes 
or stability of coronary plaques at 12 weeks (after treatment). 
However, the reduction in both the coronary and extracoro-
nary artery FDG signals, which has been validated histopatho-
logically as an inflammatory marker,12,26,29,30 suggests that the 
underlying inflammation-mediated high-risk plaque features 
may have been favorably modified. Although the image anal-
yses in our study were prespecified before initiation of any 
study procedures, future studies are warranted to confirm our 
findings.
Conclusions
In summary, we show, for the first time, that statin therapy 
results in reduction in coronary inflammation and that the anti-
inflammatory impact of statins is substantially greater within 
morphologically more advanced coronary plaques. Collec-
tively, these findings suggest one potential mechanism by 
which statins may disproportionately benefit individuals with 
more advanced atherosclerotic disease.
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Figure 6. Extracoronary arterial inflammation associates with 
coronary structural features. The positron emission tomography 
(PET)/computed tomography (CT)–derived inflammatory signal 
in the ascending aorta (target-to-background ratio [TBR]) was 
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CLINICAL PERSPECTIVE
Atherosclerotic disease is distributed inhomogeneously within the arterial wall. The presence of nonobstructive plaques, 
in particular, those with high-risk morphology, is associated with an increased risk of atherothrombosis. We tested the 
hypothesis that the anti-inflammatory effect of statins is greatest within left main coronary artery plaques containing high-
risk morphology. Herein, we provide an initial observation that statin therapy results in a reduction in left main coronary 
artery inflammation. Furthermore, we show in both coronary and extracoronary arteries that the anti-inflammatory impact of 
statins is substantially greater within plaques that contain high-risk morphology. Together, the findings suggest an additional 
mechanism by which statins may disproportionately benefit individuals with more advanced atherosclerotic disease.
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